Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
NKTR 
Nektar Therapeutics (NKTR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/17/2025: NKTR (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
8 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $96.8
1 Year Target Price $96.8
| 2 | Strong Buy |
| 2 | Buy |
| 3 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 0.23% | Avg. Invested days 26 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 461.40M USD | Price to earnings Ratio - | 1Y Target Price 96.8 |
Price to earnings Ratio - | 1Y Target Price 96.8 | ||
Volume (30-day avg) 8 | Beta 0.56 | 52 Weeks Range 6.48 - 37.38 | Updated Date 07/17/2025 |
52 Weeks Range 6.48 - 37.38 | Updated Date 07/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -9.45 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -152.49% | Operating Margin (TTM) -424.15% |
Management Effectiveness
Return on Assets (TTM) -26.8% | Return on Equity (TTM) -189.46% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 343109948 | Price to Sales(TTM) 5.29 |
Enterprise Value 343109948 | Price to Sales(TTM) 5.29 | ||
Enterprise Value to Revenue 3.93 | Enterprise Value to EBITDA -6.5 | Shares Outstanding 17300500 | Shares Floating 12233960 |
Shares Outstanding 17300500 | Shares Floating 12233960 | ||
Percent Insiders 1.29 | Percent Institutions 67.11 |
Upturn AI SWOT
Nektar Therapeutics
Company Overview
History and Background
Nektar Therapeutics, founded in 1990, is a biopharmaceutical company focusing on discovering and developing innovative medicines using its proprietary PEGylation and advanced polymer conjugate technologies. Initially focused on drug delivery, it has evolved into developing its own pipeline of immuno-oncology assets.
Core Business Areas
- Research and Development: Discovery and development of new drug candidates, primarily in immuno-oncology.
- Manufacturing: Production of PEGylation reagents and certain drug candidates for clinical trials and potential commercialization.
Leadership and Structure
Nektar's leadership team consists of seasoned pharmaceutical executives with expertise in drug development, commercialization, and finance. The company operates with a functional organizational structure, with departments dedicated to R&D, manufacturing, clinical development, and commercial operations.
Top Products and Market Share
Key Offerings
- NKTR-255: A novel IL-15 receptor agonist being developed for various cancer indications. It is in clinical trials. There are many IL-15 agonist/fusion protein that are being developed, including ALT-803 from Altor BioScience, and RO7297089 from Roche
- REZPEG (Baxdrostat): Originally licensed to Roche, this drug was aimed at treating uncontrolled hypertension, but Roche returned the rights to Nektar in late 2023 after failing to demonstrate efficacy in phase 3 trials.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high R&D costs, lengthy regulatory approval processes, and intense competition. Immuno-oncology is a rapidly growing segment within the industry, driven by advances in understanding the role of the immune system in cancer.
Positioning
Nektar Therapeutics focuses on utilizing its polymer conjugation technologies to develop novel immuno-oncology therapies. Its competitive advantage lies in its ability to create differentiated drug candidates with improved efficacy and safety profiles.
Total Addressable Market (TAM)
The global immuno-oncology market is projected to reach hundreds of billions of USD. Nektar is positioned to capture a portion of this TAM with successful development and commercialization of its pipeline assets.
Upturn SWOT Analysis
Strengths
- Proprietary PEGylation and polymer conjugation technologies
- Experienced management team
- Focus on immuno-oncology, a high-growth area
- Potentially differentiated drug candidates
Weaknesses
- Reliance on successful clinical trial outcomes
- High cash burn rate
- Competition from larger pharmaceutical companies
- History of clinical trial failures
Opportunities
- Potential partnerships with larger pharmaceutical companies
- Expansion of pipeline through internal R&D and acquisitions
- Positive clinical trial results for lead drug candidates
- Growing demand for innovative cancer therapies
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from other immuno-oncology therapies
- Patent expirations
Competitors and Market Share
Key Competitors
- BMY
- MRK
- PFE
- AZN
- RHHBY
Competitive Landscape
Nektar faces intense competition from established pharmaceutical companies with greater resources and broader product portfolios. Nektar differentiates itself through its proprietary technology and focus on novel immuno-oncology targets.
Growth Trajectory and Initiatives
Historical Growth: Data not available in the context to provide specific historical growth data.
Future Projections: Future growth is dependent on successful clinical trials and commercialization of its pipeline assets. Analyst estimates vary significantly.
Recent Initiatives: Recent initiatives include focusing on its lead immuno-oncology programs and seeking strategic partnerships.
Summary
Nektar Therapeutics is a biopharmaceutical company with a focus on immuno-oncology, leveraging its proprietary PEGylation technology. The company's success hinges on the clinical trial outcomes of its lead drug candidates, particularly NKTR-255. It faces substantial risks due to high cash burn and competition from larger pharmaceutical players. Positive clinical data and strategic partnerships are crucial for its future growth, with focus on early-stage clinical assets.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Industry publications
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Nektar Therapeutics
Exchange NASDAQ | Headquaters San Francisco, CA, United States | ||
IPO Launch date 1994-05-03 | CEO, President & Director Mr. Howard W. Robin | ||
Sector Healthcare | Industry Biotechnology | Full time employees 61 | Website https://www.nektar.com |
Full time employees 61 | Website https://www.nektar.com | ||
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders in the United States and internationally. It develops NKTR-358, a regulatory T (Treg) cell stimulator designed to address the imbalance in the immune system underlying autoimmune disorders and chronic inflammatory conditions; PEG-CSF1, a polyethylene glycol (PEG) modified hematopoietic colony stimulating factor protein that is engineered to selectively modulate resolution processes of inflammation and has applications in a number of therapeutic indications, including acute and chronic inflammation; Tumor necrosis factor (TNF) receptor type II (TNFR2) agonist asset is a bivalent antibody molecule used to selectively stimulate TNFR2 receptor activity, without modulation of the TNFR1 signaling; and NKTR-255, an IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.